Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Telix Pharmaceuticals experienced a significant increase in trading volume, with 67,790 shares traded, up 53% from the previous session.
• Analysts maintain a Buy rating for TLX, with an average price target of $22.33, reflecting optimism in the company's prospects.
• Recently, several institutional investors have purchased stakes in Telix Pharmaceuticals, indicating growing interest and confidence in the company.

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw strong trading volume on Monday . 67,790 shares were traded during trading, an increase of 53% from the previous session's volume of 44,246 shares.The stock last traded at $12.28 and had previously closed at $12.48.

Analyst Upgrades and Downgrades

Several research firms recently commented on TLX. Wedbush reissued an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Finally, HC Wainwright started coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $22.33.

Telix Pharmaceuticals Trading Down 1.8%

The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The stock's 50-day simple moving average is $14.47 and its two-hundred day simple moving average is $16.25.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC bought a new position in Telix Pharmaceuticals in the first quarter worth about $170,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000. Blair William & Co. IL purchased a new stake in Telix Pharmaceuticals during the second quarter valued at approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals during the second quarter worth $297,000. Finally, ABC Arbitrage SA purchased a new stake in Telix Pharmaceuticals in the first quarter valued at about $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.